Improving the standard of care(1)(2)
PsyBio Therapeutics (“PsyBio” or the “Company”) is a biotechnology company developing a portfolio of psychoactive compounds targeted for the treatment of mental health challenges and other disorders.
The Company has a collaboration with Miami University, Oxford Ohio where they have filed intellectual property for biosynthesized psilocybin, it’s intermediates, and other molecules.
With a proprietary platform technology, the Company is in the process of developing new drugs by producing novel psychoactive molecules from genetically modified bacteria. The platform is expected to enable the rapid generation of highly stable compounds far cheaper, faster and greener than any other published method.
Currently working in the laboratory on over twenty psychedelically inspired compounds from different fungi and plants with unique psychoactive properties.
PsyBio is in the process of preparing the initial molecules for clinical batch manufacturing and concurrently preparing an investigational new drug (“IND”) application to study the compounds in patients with cancer related depression.
Certain statements regarding psilocybin, it’s intermediates, and other molecules have not been evaluated by the Food and Drug Administration or other similar regulatory authorities, nor has the efficacy of psilocybin, it’s intermediates, and other molecules been confirmed by FDA approved research. There is no assurance that psilocybin, it’s intermediates, and other molecules can be used to diagnose, treat, cure or prevent any disease or condition. Robust scientific research and clinical trials are needed.
Subject to receipt of all necessary approvals, including as applicable, governmental authorities and the academic and scientific organizations with which PsyBio is working with. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocybin, it’s intermediates, and other molecules.